Article Information
History
- July 12, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Ryan Fischera,
- Pat Furlonga,
- Annie Kennedyb,
- Kelly Maynardc,d,
- Marissa Penrodd,e,
- Debra Millerf,
- Chamindra G. Laverty, MDg,
- Linda Lowes, PhDh,
- Nancy L. Kuntz, MDi,
- Perry B. Shieh, MD, PhDj,
- Jane Kondejewski, PhDk,
- Peter J. Neumann, ScDl,
- Jason Shafrin, PhDm and
- Richard J. Willke, PhDn,*
- aParent Project Muscular Dystrophy, Washington, DC;
- bEveryLife Foundation for Rare Diseases, Washington DC;
- cLittle Hercules Foundation, Dublin, OH;
- dDuchenne Family Assistance Program;
- eTeam Joseph, West Bloomfield, MI;
- fCureDuchenne, Newport Beach, CA;
- gUC San Diego, San Diego, CA;
- hNationwide Children’s Hospital, Columbus, OH;
- iNorthwestern University Feinberg School of Medicine, Chicago, IL;
- jUCLA, Los Angeles, CA;
- kSNELL Medical Communication, Inc., Montreal, QC;
- lCenter for Evaluation of Value and Risk in Medicine, Boston, MA;
- mFTI Consulting, Los Angeles, CA;
- nInternational Society for Pharmacoeconomics and Outcomes Research, Lawrenceville, NJ
- ↵*Corresponding Author: Richard J. Willk 1622 Channel Front Court, Soddy Daisy, TN 37379 rwillke{at}ispor.org 908-672-4156
Posted July 12, 2023.
Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy Therapies
